5th Annual Drug Development Congress 2013

  • Conference Call
  • Oxford Global Conferences Ltd are proud to present the 5th Annual Drug Development Congress, taking place on the 10th & 11th June, 2013 in Geneva, Switzerland.

    It is estimated that the average drug costs the world’s leading pharmaceutical companies at least $4 billion to develop. Amid fears that the current large pharma model is not working, this event focuses on attempts to break down discovery and development boundaries and promote knowledge share between therapy areas.

    To maintain the extensive networking opportunities enjoyed by last year’s delegates, the development congress will once again be co-located with our discovery summit. The 14th Annual Drug Discovery Leaders’ Summit has a long-held association with the leaders in medicinal chemistry and drug design. This year’s event will focus on innovation. Experts will discuss how new developments in screening, assay development, structure-activity analysis and anti-target effect prediction will influence the success of discovery portfolios.

    Agenda

    Day 1 – Drug Development: Overcoming Key Challenges

    • Safety & Toxicity Assessment
    • Predicting Human Pharmacokinetics
    • Translational Modelling Approaches
    • Developing Biologics: Safety & Immunogenicity Concerns
    • Assay Development & Validation
    • NGS Applications For Drug Development

    Day 2 – Improving Decision Making & Fostering Collaboration

    • Breaking Down Boundaries Between Discovery & Development
    • Improving Decision Making Through Biomarkers & Imaging
    • Integrating Toxicology Studies Earlier In The Pipeline
    • External Collaboration: Public/Private Collaboration
    • Internal Collaboration: Translating Data And Transferring Processes

    Submit a poster

    For attendees interested in submitting a poster, there are opportunities now available. Your poster presentation will be located in the exhibition room for two days alongside other posters from senior scientists working in industry and academia.

    How to submit your poster

    We will require:

    • Poster title
    • Abstract (200 words or less)
    • Principal author
    • Organisation
    • Mailing address
    • Email
    • Telephone
    • Fax
    • Additional authors

    In order to secure your board space a fee of £125 will be required. The poster should be presented as A0 (841mm x 1189mm) portrait size. To take advantage of this opportunity you need to be registered as a paid delegate over the 2 days. We have limited spaces available, to please register soon!

    Speakers

    Our speaker programmes are carefully researched each year to ensure that delegates are exposed to the highest level of expertise. However, delegates not only benefit from the experience of our speakers, but also gain an insight into the experiences of other attendees – Q&A sessions and panel discussions are utilised to enable sharing of knowledge and facilitate idea exchange.

    If you have a cutting edge case study or relevant presentation and would like to join the speaker panel at one of our events, please contact Charlotte Tighe at c.tighe@oxfordglobal.co.uk

    Confirmed speakers

    • Bhupinder Bhullar - Lab Head, Development Molecular Pathways, Novartis
    • Simon Chivers - Senior Safety Assessment Expert, Novartis
    • Andreas Czich - Head Preclinical Safety Germany, Sanofi
    • Sjef De Kimpe - VP Early Drug Development, Prosensa
    • Stefania Di Marco - Senior Research Fellow, Okairos
    • Nicholas Ferenc - Director, Personalized Medicine and Companion Diagnostics Strategy, Sanofi
    • Peter Greasley - Translational Science Director, AstraZeneca
    • Andrea Greiter-Wilke - Head Safety Pharmacology, Roche
    • Christopher Hart - Clinical Information Science Director - Oncology Clinical Discovery Team, AstraZeneca
    • Joachim Höechel - Head Clinical Pharmacokinetics WH/STH/CMR, Bayer HealthCare
    • Joel Krauser - Director - DMPK/Isotope Laboratories (EU), Novartis
    • Thierry Lave - Head DMPK Modeling and Simulation, Roche
    • Tom Loughman - Director of API Development, Ipsen
    • Tomas Mow - Head of Department Exploratory Toxicology, H. Lundbeck A/S
    • John Pears - Director, Safety Science, AstraZeneca
    • Harald Petry - VP, Research & Development, Uniqure
    • Francois Pognan - Executive Director - Biochemical & Translational Safety, Novartis
    • Prakesh Purohit - Associate Director, Scientific Affairs, Ipsen
    • Will Spooren - Group Leader Behavioural Pharmacology, Roche
    • Camilla Staahl - Associate Director Translational Medicine, Grunenthal
    • Robert Williams - Chief Drug Development Scientist, Cancer Research UK

    Who Will Attend

    The 5th Annual Drug Development Congress is an exclusive event designed for senior level attendees from leading pharmaceutical and biotechnology organisations, along with highly esteemed members of academic and government institutions. Delegates typically include VPs, Directors and Global Heads of:

    • ADME
    • Biomarkers
    • Biopharmaceuticals
    • Imaging
    • Immunogenicity
    • Modelling & Simulation
    • Pharmacology
    • PK/PD
    • Research & Development
    • Safety
    • Toxicology
    • Translational Research
    starting: ending: 11.06.2013 Location: , Category:

    Timeline

    Conference START 11.06.2013 END

    All deadlines have expired!

    This conference has no more open deadlines. There may be successive conferences coming up you may by interested in.

    Please check our conference list and search...

    Conference Facts

    Location , Address InterContinental Geneva, Chemin du Petit-Saconnex 7-9 Category Organiser More Info Conference Website

    Further interesting Conferences

    Currently we have no similar events listed. Please check our website regulary, subscribe to our RSS-Feed or follow us on twitter for new listings.